PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
September 25, 20240 citations

Supplementary Figure 1 from Differential Distribution of the DNA-PKcs Inhibitor Peposertib Selectively Radiosensitizes Patient-derived Melanoma Brain Metastasis Xenografts

View Full Paper
JJJianxiong JiSDSonja DragojevicCCCameron M. Callaghan

Key Points

Key points are not available for this paper at this time.

Abstract

Supplemental Figure 1 shows bar graph of quantification of cells that have >25 gH2AX foci per cell in M15 cell line, after treatment with peposertib and radiation

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Ji et al. (2024) studied this question.

synapsesocial.com/papers/68e5778bb6db6435875173edhttps://doi.org/10.1158/1535-7163.27102355.v1
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Supplementary Figure 1 from Differential Distribution of the DNA-PKcs Inhibitor Peposertib Selectively Radiosensitizes Patient-derived Melanoma Brain Metastasis Xenografts2024
  2. 2Supplementary Figure 1 from Differential Distribution of the DNA-PKcs Inhibitor Peposertib Selectively Radiosensitizes Patient-derived Melanoma Brain Metastasis Xenografts2024
  3. 3Supplementary Figure 1 from Differential Distribution of the DNA-PKcs Inhibitor Peposertib Selectively Radiosensitizes Patient-derived Melanoma Brain Metastasis Xenografts2024
  4. 4Supplementary Figure 2 from Differential Distribution of the DNA-PKcs Inhibitor Peposertib Selectively Radiosensitizes Patient-derived Melanoma Brain Metastasis Xenografts2024
  5. 5Supplementary Figure 2 from Differential Distribution of the DNA-PKcs Inhibitor Peposertib Selectively Radiosensitizes Patient-derived Melanoma Brain Metastasis Xenografts2024